PMV Pharmaceuticals Inc. (PMVP): Price and Financial Metrics


PMV Pharmaceuticals Inc. (PMVP): $15.33

2.12 (+16.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PMVP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PMVP Stock Price Chart Interactive Chart >

Price chart for PMVP

PMVP Price/Volume Stats

Current price $15.33 52-week high $37.32
Prev. close $13.21 52-week low $11.44
Day low $14.73 Volume 8,938,000
Day high $18.12 Avg. volume 986,537
50-day MA $16.88 Dividend yield N/A
200-day MA $21.49 Market Cap 698.65M

PMV Pharmaceuticals Inc. (PMVP) Company Bio


PMV Pharmaceuticals, Inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.


PMVP Latest News Stream


Event/Time News Detail
Loading, please wait...

PMVP Latest Social Stream


Loading social stream, please wait...

View Full PMVP Social Stream

Latest PMVP News From Around the Web

Below are the latest news stories about PMV Pharmaceuticals Inc that investors may wish to consider to help them evaluate PMVP as an investment opportunity.

PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day

CRANBURY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will represent PMV Pharmaceuticals in a “Fireside Chat” at the Guggenheim Healthcare Talks 2022 Oncology Day taking place on February 9, 2022. The company will also participate in one-on-one

Yahoo | February 3, 2022

Thinking about buying stock in Nextplay Technologies, Vinco Ventures, Orchid Island Capital, Altria Group, or PMV Pharmaceuticals?

NEW YORK , Jan. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NXTP, BBIG, ORC, MO, and PMVP. Full story available on Benzinga.com

Benzinga | January 14, 2022

Do Hedge Funds Love PMV Pharmaceuticals, Inc. (PMVP)?

We at Insider Monkey have gone over 867 13F filings that hedge funds and prominent investors are required to file by the SEC.

Insider Monkey | January 12, 2022

PMV Pharma Announces Changes to its Board of Directors

CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Kirsten Flowers to its Board of Directors. Concurrent with the appointment of Ms. Flowers, Peter Thompson, M.D. will resign from PMV’s Board. “Peter has been an invaluable member of the Board during a period of substantial growth and

Yahoo | January 6, 2022

We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 20, 2021

Read More 'PMVP' Stories Here

PMVP Price Returns

1-mo 1.12%
3-mo -5.02%
6-mo -30.91%
1-year -55.44%
3-year N/A
5-year N/A
YTD -33.64%
2021 -62.45%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5705 seconds.